New Late Breaking Preliminary Data Demonstrate Balt’s Squid™ Liquid Embolic May Improve Outcomes in Patients with Chronic Subdural Hematomas
Retrieved on:
Friday, February 9, 2024
Randomized controlled trial, Balts, Veterans' affairs, Embolization, FDA, Prevalence, STEM, Disability, Conference, University, SDH, Physician, MPH, United, MMA, IDE, Incidence, Epidural hematoma, Patient, Person, Stony Brook University Hospital, Ageing, Disease, Doctor of Philosophy, Death, Pharmaceutical industry
The preliminary data demonstrates that rates of complications thus far are low and embolizing the MMA for the treatment of Chronic Subdural Hematoma (cSDH) potentially improves the success rates of both surgical and non-surgical treatments.
Key Points:
- The preliminary data demonstrates that rates of complications thus far are low and embolizing the MMA for the treatment of Chronic Subdural Hematoma (cSDH) potentially improves the success rates of both surgical and non-surgical treatments.
- Standard management included surgical drainage of the subdural hemorrhage for qualified patients and best medical management for patients who did not require surgery.
- STEM, which completed enrollment last year, is the first prospective IDE trial investigating embolization of the MMA for the treatment of chronic Sub-Dural Hematoma (cSDH).
- A Veterans Affairs (VA) study of cSDH found a prevalence rate of 79.4 per 100,000 persons.